Yazar "Sezgin G." seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim Yok
    Yayın
    Acute motor axonal neuropathy: A severe complication of alcohol abuse
    (2010) Sahin S.; Cinar N.; Sezgin G.; Ayalp S.; Karsidag S.
    …
  • Küçük Resim Yok
    Yayın
    Effects of spirulina on cyclophosphamide-induced ovarian toxicity in rats: Biochemical and histomorphometric evaluation of the ovary
    (2013) Yener N.A.; Sinanoglu O.; Ilter E.; Celik A.; Sezgin G.; Midi A.; Deveci, Uğur; Aksungar F.; Deveci, Uğur
    Cyclophosphamide (Cyc) is known to cause ovotoxicity and infertility in women. Our aim is to investigate the possible ovotoxic effects of Cyc and possible antioxidant and protective effects of blue-green algae, Spirulina (Sp), in rat ovaries. Eighteen rats were given: group I (n = 6, control); group II (n = 6, CP), a single dose Cyc; group III (n = 6, Sp+Cyc), 7 days Sp+single dose Cyc. Tissue malondialdehyde (MDA) levels, superoxide dismutase (SOD), and catalase (CAT) activities are assessed biochemically. Normal and atretic primordial and primary follicle counts for all sections obtained for each ovary are calculated. Mean number of follicle counts for each group are compared. In Sp+Cyc group, tissue MDA levels were significantly lower than those in the CP and higher than those in the C group (CP > Sp + Cyc > C). Tissue SOD activity was significantly higher in Sp+Cyc group than that in the CP group and lower than that in the C group (C > Sp + Cyc > C). No statistically significant difference was found between the ovarian CAT activities in any group. Histomorphometrically, there was also no significant difference between the mean numbers of normal and atretic small follicle counts. Our results suggest that single dose Cyc has adverse effects on oxidant status of the ovaries and Sp has protective effects in Cyc-induced ovotoxicity. © 2013 Nese Arzu Yener et al.
  • Küçük Resim Yok
    Yayın
    Long term follow-up of five patients with acute intermittent porphyria, case based clinical study [Uzun süreli takip edilen akut intermitant porfiryali beş hastanin klinik temelli bulgularina ait çalişma]
    (Nobelmedicus, 2016) Sezgin G.
    Porphyrias are among rare group of inherited diseases emerging due to decreased enzymes which have the role of the biosynthesis of the hem. The most common and the most serious form is acute intermittent porphyria (AIP) which is an autosomal dominant disease. Gastrointestinal and neuropsychiatric symptoms can be seen at the patients. Five cases who had been followed 2-23 years after the diagnosis, were presented in this paper. Three cases were brothers, one case was father and daughter, and the other case was a male from different family. Symptoms were first seen between ages 15-39. Two cases showed long and severe attacks which were characterized by symptoms of the autonomic and peripheral nervous system. Abdominal pain for other three cases and neurologic signs for the fifth case were distinctive. Porphobilinogen, protoporphyrin and aminolevulinic acide were high in the urine of every patient. All patients were provided benefits from intravenous hem treatment. Second case was deceased on 19th year of the follow-up, due to multi organ failure after myocardial infarction. As a conclusion; even though porphyria is an easily diagnosable disease, main problem is that there is little knowable and little awareness of the disease. Patients can apply with different clinical appearance and it is interesting that the disease is highly sensitive to the environmental factors and comorbidities. © 2016 Nobelmedicus. All rights reserved.
  • Küçük Resim Yok
    Yayın
    Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey - GALATA study
    (Informa Healthcare, 2015) Ayvaz G.; Keskin L.; Akin T.F.; Dokmetas H.S.; Tasan E.; Ar I.B.; Uren E.; Akber T.; Akdeniz Y.; Bambul N.; Bayraktaroglu T.; Borlu F.; Boz M.; Bozoglu E.; Buyukbese M.A.; Canberk A.; Comlekci A.; Delibasi T.; Demir S.; Eskioglu E.; Guler S.; Gulkan S.; Hekimsoy Z.; Karaca Z.; Keskin M.; Koca N.; Korkmaz H.; Onder E.; Ozisik L.; Peru C.; Sahin M.; Saygili F.; Serin S.; Sezer H.; Sezgin G.; Tasci I.; Tasliyurt T.; Torun A.N.; Tura Bahadir C.; Gursoy Yener G.; Yigit Z.
    Objective: To evaluate tolerability/safety and the efficacy of the combination of vildagliptin plus metformin in a real-life population of patients with type 2 diabetes mellitus (T2DM). Research design and methods: This multicenter, single-arm, 6 month, observational, prospective cohort study was conducted at 39 centers across Turkey. T2DM patients on vildagliptin and metformin for ?4 weeks were enrolled regardless of their previous antidiabetic therapy. Main outcome measures: Efficacy was evaluated by measuring hemoglobin A1c (HbA1c) levels. Tolerability/safety parameters evaluated included hypoglycemic events, gastrointestinal events, peripheral edema and weight gain. Results: This study enrolled 665 patients with a mean±standard deviation (SD) age of 55.1±10.2 years and female predominance (n=394, 59.2%). Safety was assessed in all enrolled patients. Hypoglycemia was reported in 10 (1.5%) patients (95% confidence interval = 0.8-2.7%). Efficacy was assessed in 289 (43.5%) patients treated for 6±1 months; these patients showed a mean decrease in HbA1c of 0.8% from baseline value of 7.8% (p<0.001). The percentages of patients who achieved HbA1c targets of ?6.5% and ?7.0% were significantly increased, from 10.7% to 33.6% and from 22.1% to 52.6%, respectively (p<0.001 each). The decrease in HbA1c was independent of baseline HbA1c (?8% vs. 8-10% vs. ?10%), age (?65 vs. >65 years) and body mass index (<30 vs. ?30 kg/m2) (p<0.001 each). In total, 136 adverse events (AEs) were observed in 71 (10.7%) patients; 10 (1.5%) patients experienced hypoglycemia and gastrointestinal AEs were most commonly reported (n=29, 4.4%). Conclusions: In a 'real-life' setting, the vildagliptin and metformin combination was associated with significant improvements in reaching target HbA1c levels, even in elderly and obese patients with T2DM. Moreover, vildagliptin and metformin demonstrated a good overall tolerability/safety profile. © 2015 All rights reserved: reproduction in whole or part not permitted.